{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:30:40Z","timestamp":1771039840451,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Hospital Pharmacy Foundation of Jiangsu Pharmaceutical Association","award":["A201606"],"award-info":[{"award-number":["A201606"]}]},{"name":"Hospital Pharmacy Foundation of Jiangsu Pharmaceutical Association","award":["A201810"],"award-info":[{"award-number":["A201810"]}]},{"name":"Specially Appointed Medical Expert Project of Jiangsu Commission of Health"},{"name":"Medical Science and Technique Foundation of Nanjing Health Commission","award":["YKK18147"],"award-info":[{"award-number":["YKK18147"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.intimp.2020.106290","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T06:40:56Z","timestamp":1581316856000},"page":"106290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Tacrolimus treatment in childhood refractory nephrotic syndrome: A retrospective study on efficacy, therapeutic drug monitoring, and contributing factors to variable blood tacrolimus levels"],"prefix":"10.1016","volume":"81","author":[{"given":"Hong-Li","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie-Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Lei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze-Yue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze-Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan-Sheng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2020.106290_b0005","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/ki.2012.280","article-title":"The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines\u2013application to the individual patient","volume":"82","author":"Radhakrishnan","year":"2012","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.intimp.2020.106290_b0010","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/13543784.16.7.1099","article-title":"Tacrolimus in the treatment of idiopathic nephrotic syndrome","volume":"16","author":"Westhoff","year":"2007","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"10141","key":"10.1016\/j.intimp.2020.106290_b0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","article-title":"Idiopathic nephrotic syndrome in children","volume":"392","author":"Noone","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.intimp.2020.106290_b0020","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2352-4642(18)30283-9","article-title":"Management of steroid-resistant nephrotic syndrome in children and adolescents","volume":"2","author":"Tullus","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"12","key":"10.1016\/j.intimp.2020.106290_b0025","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/17425255.2017.1395413","article-title":"Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients","volume":"13","author":"Andrews","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"8","key":"10.1016\/j.intimp.2020.106290_b0030","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","article-title":"Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus","volume":"51","author":"Kamdem","year":"2005","journal-title":"Clin. Chem."},{"issue":"9","key":"10.1016\/j.intimp.2020.106290_b0035","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1124\/dmd.112.045302","article-title":"Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs","volume":"40","author":"Walsky","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.intimp.2020.106290_b0040","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1124\/dmd.114.057000","article-title":"Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide)","volume":"42","author":"Tseng","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.intimp.2020.106290_b0045","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","article-title":"PharmGKB summary: cyclosporine and tacrolimus pathways","volume":"23","author":"Barbarino","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"issue":"1","key":"10.1016\/j.intimp.2020.106290_b0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","article-title":"Clinical determinants of calcineurin inhibitor disposition: a mechanistic review","volume":"48","author":"Vanhove","year":"2016","journal-title":"Drug Metab. Rev."},{"issue":"16","key":"10.1016\/j.intimp.2020.106290_b0055","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2217\/pgs-2017-0131","article-title":"Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22?","volume":"18","author":"Elens","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/j.intimp.2020.106290_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102413","article-title":"Impact of CYP3A5, POR, and CYP2C19 polymorphisms on trough concentration to dose ratio of tacrolimus in allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Suetsugu","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2020.106290_b0065","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/ndt\/gfy096","article-title":"Increase in tacrolimus exposure after steroid tapering is influenced by CYP3A5 and pregnane X receptor genetic polymorphisms in renal transplant recipients","volume":"33","author":"Stifft","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"10.1016\/j.intimp.2020.106290_b0070","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/liv.13597","article-title":"Association of donor small ubiquitin-like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation","volume":"38","author":"Zhang","year":"2018","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.intimp.2020.106290_b0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1470320313512390","article-title":"Genetic variants of ACE (Insertion\/Deletion) and AGT (M268T) genes in patients with diabetes and nephropathy","volume":"15","author":"Shaikh","year":"2014","journal-title":"J. Renin. Angiotensin Aldosterone Syst."},{"issue":"11","key":"10.1016\/j.intimp.2020.106290_b0080","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/FPC.0b013e32830e1e16","article-title":"Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease","volume":"18","author":"Smith","year":"2008","journal-title":"Pharmacogenet. Genomics"},{"issue":"6","key":"10.1016\/j.intimp.2020.106290_b0085","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/clpt.2009.195","article-title":"Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology","volume":"86","author":"Leeder","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"24","key":"10.1016\/j.intimp.2020.106290_b0090","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.2174\/1381612824666180829101836","article-title":"Individualized tacrolimus therapy for pediatric nephrotic syndrome: considerations for ontogeny and pharmacogenetics of CYP3A","volume":"24","author":"Sun","year":"2018","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.intimp.2020.106290_b0095","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1542\/peds.105.6.1242","volume":"105","author":"Hogg","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.intimp.2020.106290_b0100","doi-asserted-by":"crossref","unstructured":"KDIGO Clinical Practice Guideline for Glomerulonephritis work group, Chapter 4: Steroid-resistant nephrotic syndrome in children, Kidney Int. Suppl. (2011) 2(2) (2012) 172\u2013176.","DOI":"10.1038\/kisup.2012.17"},{"issue":"11","key":"10.1016\/j.intimp.2020.106290_b0105","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00467-012-2228-3","article-title":"Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome","volume":"27","author":"Wang","year":"2012","journal-title":"Pediatr. Nephrol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106290_b0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nep.12537","article-title":"Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome","volume":"21","author":"Wang","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.intimp.2020.106290_b0115","article-title":"Efficacy and safety of tacrolimus and low-dose prednisone in Chinese children with steroid-resistant nephrotic syndrome","author":"Chen","year":"2019","journal-title":"World J. Pediatr."},{"issue":"1","key":"10.1016\/j.intimp.2020.106290_b0120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/jim-2016-000163","article-title":"Comparison of second-line immunosuppressants for childhood refractory nephrotic syndrome: a systematic review and network meta-analysis","volume":"65","author":"Fu","year":"2017","journal-title":"J. Invest. Med."},{"key":"10.1016\/j.intimp.2020.106290_b0125","doi-asserted-by":"crossref","unstructured":"KDIGO Clinical Practice Guideline for Glomerulonephritis work group, Chapter 3: Steroid-sensitive nephrotic syndrome in children, Kidney Int Suppl (2011) 2(2) (2012) 163\u2013171.","DOI":"10.1038\/kisup.2012.16"},{"issue":"11","key":"10.1016\/j.intimp.2020.106290_b0130","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00467-015-3133-3","article-title":"Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome","volume":"30","author":"Jahan","year":"2015","journal-title":"Pediatr. Nephrol."},{"issue":"10","key":"10.1016\/j.intimp.2020.106290_b0135","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.2012.238","article-title":"Treatment with tacrolimus and prednisone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome","volume":"82","author":"Gulati","year":"2012","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.intimp.2020.106290_b0140","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2013.12.002","article-title":"Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children","volume":"63","author":"Samuel","year":"2014","journal-title":"Am. J. Kidney Dis."},{"issue":"8","key":"10.1016\/j.intimp.2020.106290_b0145","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/bcp.13605","article-title":"Population pharmacokinetics of tacrolimus in children with nephrotic syndrome","volume":"84","author":"Hao","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2020.106290_b0150","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00228-013-1501-0","article-title":"Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation","volume":"69","author":"Guy-Viterbo","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106290_b0155","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/clpt.2009.210","article-title":"Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients","volume":"86","author":"Zhao","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2020.106290_b0160","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s40262-016-0390-7","article-title":"The effect of weight and CYP3A5 genotype on the population pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients","volume":"55","author":"Prytula","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.intimp.2020.106290_b0165","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200645040-00002","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age","volume":"45","author":"Perucca","year":"2006","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.intimp.2020.106290_b0170","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-013-0067-4","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update","volume":"52","author":"Italiano","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.intimp.2020.106290_b0175","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.intimp.2020.106290_b0180","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/sj.bmt.1702588","article-title":"Tacrolimus clearance is age-dependent within the pediatric population","volume":"26","author":"Przepiorka","year":"2000","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.intimp.2020.106290_b0185","first-page":"4023","article-title":"Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models","volume":"17","author":"Wang","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"10.1016\/j.intimp.2020.106290_b0190","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00228-018-2604-4","article-title":"Diltiazem used as a tacrolimus-sparing agent for treatment of pediatric patients with refractory nephrotic syndrome: a case report and retrospective analysis","volume":"75","author":"Sun","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2020.106290_b0195","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/archdischild-2017-313788","article-title":"Off-label use of tacrolimus in children with Henoch-Schonlein purpura nephritis: a pilot study","volume":"103","author":"Zhang","year":"2018","journal-title":"Arch. Dis. Child."},{"issue":"1","key":"10.1016\/j.intimp.2020.106290_b0200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2020.106290_b0205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijpharm.2012.05.079","article-title":"Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children","volume":"452","author":"Hines","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.intimp.2020.106290_b0210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/0971-4065.107197","article-title":"Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome","volume":"23","author":"Sinha","year":"2013","journal-title":"Indian J. Nephrol."},{"issue":"9","key":"10.1016\/j.intimp.2020.106290_b0215","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/ndt\/gfq813","article-title":"Renal interstitial fibrosis in children treated with FK506 for nephrotic syndrome","volume":"26","author":"Morgan","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.intimp.2020.106290_b0220","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/nep.12392","article-title":"Chronic nephrotoxicity limits successful use of Tacrolimus in the management of adult steroid-dependent minimal change disease","volume":"20","author":"Ramachandran","year":"2015","journal-title":"Nephrology (Carlton)"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919329005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919329005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:15:12Z","timestamp":1761585312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919329005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":44,"alternative-id":["S1567576919329005"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106290","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tacrolimus treatment in childhood refractory nephrotic syndrome: A retrospective study on efficacy, therapeutic drug monitoring, and contributing factors to variable blood tacrolimus levels","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106290"}}